Intended for healthcare professionals

Head To Head Head to Head

Are clinical trial data shared sufficiently today? Yes

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f1881 (Published 09 July 2013) Cite this as: BMJ 2013;347:f1881
  1. John Castellani, president and chief executive officer, Pharmaceutical Research and Manufacturers of America (PhRMA)
  1. Contact via Matthew Bennett: MBennett{at}phrma.org

The AllTrials campaign asks for all trials to be registered and their results published. Ben Goldacre (doi:10.1136/bmj.f1880) says we need the evidence to make informed decisions about medicines. John Castellani says mandatory disclosure could affect patient privacy, stifle discovery, and allow competitors or unscrupulous actors to use the information

Clinical trials are essential for the successful development of new medicines that save and improve lives and provide hope for millions of patients. Biopharmaceutical companies are committed to the continuous improvement of clinical trials to bring innovative medicines to the patients who need them. This includes protecting the safety of study participants, overcoming barriers to greater participation, and fostering new medical discoveries.

The biopharmaceutical industry is firmly committed to enhancing public health through responsible reporting and publication of clinical research and safety information. In the process of drug development, companies routinely publish their research, collaborate with academic researchers, and disclose clinical trial information at the time of patient registration, drug approval, and for medicines whose research programs have been discontinued. …

View Full Text